Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis

Ling Ding, Chenfei Zhu, Fei Yu, Pengkai Wu, Gang Chen, Aftab Ullah, Kaikai Wang, Minjie Sun, Jing Li, David Oupicky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung. The results of this study provide first evidence of the potential benefits of combined inhibition of CXCR4 and PAI-1 in the pulmonary treatment of PF.

Original languageEnglish (US)
Pages (from-to)1765-1776
Number of pages12
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number6
DOIs
StatePublished - Aug 2018

Fingerprint

Polyamideimides
Polyetherimides
Plasminogen Activator Inhibitor 1
Gene Silencing
Pulmonary Fibrosis
Fibrosis
Genes
Lung
Bleomycin
Fibroblasts
Collagen
Derivatives
Small Interfering RNA
Down-Regulation
Plasminogen Inactivators
Safety

Keywords

  • CXCR4
  • Intratracheal administration
  • PAI-1
  • Pulmonary fibrosis
  • siRNA

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis. / Ding, Ling; Zhu, Chenfei; Yu, Fei; Wu, Pengkai; Chen, Gang; Ullah, Aftab; Wang, Kaikai; Sun, Minjie; Li, Jing; Oupicky, David.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 6, 08.2018, p. 1765-1776.

Research output: Contribution to journalArticle

Ding, Ling ; Zhu, Chenfei ; Yu, Fei ; Wu, Pengkai ; Chen, Gang ; Ullah, Aftab ; Wang, Kaikai ; Sun, Minjie ; Li, Jing ; Oupicky, David. / Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 6. pp. 1765-1776.
@article{0c663f99cf494b06b11e71e37d1be899,
title = "Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis",
abstract = "This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung. The results of this study provide first evidence of the potential benefits of combined inhibition of CXCR4 and PAI-1 in the pulmonary treatment of PF.",
keywords = "CXCR4, Intratracheal administration, PAI-1, Pulmonary fibrosis, siRNA",
author = "Ling Ding and Chenfei Zhu and Fei Yu and Pengkai Wu and Gang Chen and Aftab Ullah and Kaikai Wang and Minjie Sun and Jing Li and David Oupicky",
year = "2018",
month = "8",
doi = "10.1016/j.nano.2018.05.005",
language = "English (US)",
volume = "14",
pages = "1765--1776",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis

AU - Ding, Ling

AU - Zhu, Chenfei

AU - Yu, Fei

AU - Wu, Pengkai

AU - Chen, Gang

AU - Ullah, Aftab

AU - Wang, Kaikai

AU - Sun, Minjie

AU - Li, Jing

AU - Oupicky, David

PY - 2018/8

Y1 - 2018/8

N2 - This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung. The results of this study provide first evidence of the potential benefits of combined inhibition of CXCR4 and PAI-1 in the pulmonary treatment of PF.

AB - This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung. The results of this study provide first evidence of the potential benefits of combined inhibition of CXCR4 and PAI-1 in the pulmonary treatment of PF.

KW - CXCR4

KW - Intratracheal administration

KW - PAI-1

KW - Pulmonary fibrosis

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85048532248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048532248&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.05.005

DO - 10.1016/j.nano.2018.05.005

M3 - Article

C2 - 29777878

AN - SCOPUS:85048532248

VL - 14

SP - 1765

EP - 1776

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 6

ER -